H.C. Wainwright raised the firm's price target on NeuroPace to $20 from $19 and keeps a Buy rating on the shares following quarterly results. According to management, the company has reached new all-time highs in active prescribers, accounts and patient pipeline. In view of the strong momentum, management has increased 2026 revenue guidance to $99M-$101M, up from $98M-$100M, representing 21%-23% growth of the core RNS business. Notably, the revenue guidance excludes any contribution from idiopathic generalized epilepsy indication expansion, Wainwright adds.
